Asmacure has started enrolling patients for a Phase 2 trial of its ASM-024 inhalation powder in patients with moderate and severe COPD, the company has announced. The company said that it has also completed dosing in a Phase 2 study of ASM-024 for the treatment of asthma and expects to report data early in 2014.
ASM-024 has both nicotinic and muscarinic effects. Earlier Phase 2 studies were conducted with an inhalation solution formulation delivered by nebulizer.
Asmacure Founder and Chief Medical Officer Yvon Cormier said, “Asthma and COPD represent a significant unmet medical need, as many patients with moderate-to-severe disease are not adequately controlled on existing therapies, even with increasing doses. With its potentially potent combination of smooth muscle relaxation, muscarinic blocking activity and anti-inflammatory effect, we believe ASM-024 has significant potential as an adjunct to standard of care for chronic maintenance of these two challenging diseases.”
Read the Asmacure press release.
